Summary:
This is a two part study comparing CHS-0214(study medication) to Enbrel in patients with chronic plaque psoriasis who have not yet received any biologic therapy for any indication (other than insulin or hormones).
Qualified Participants Must:
• Be 18 years of age and older
•
Have a PsO diagnosis for 6 months
•
Have an active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5)
•
Have a Body Surface Area (BSA) involved with PsO greater than or equal to 10%
•
Have a Dermatology Life Quality Index (DQLI) greater than or equal to 10
•
Have previously received phototherapy or systemic non-biologic therapy for PsO
Exclusion Criteria:
•
Not have forms of Psoriasis other than PsO
•
Not have drug induced Psoriasis
•
Not have positive QuantiFERON-tuberculosis (TB) Gold Test
•
Not have presence of significant comorbid conditions
•
Not have chemistry and hematology values outside protocol specified range
•
Not have major systemic infections
Qualified Participants May Receive:
$40 per each completed visit. 10 visits total.